As INmune CEO Raymond Tesi, M.D., said on an earnings call last month, the company designed the phase 2 trial to show “what happens in Alzheimer's disease when you properly target neuroinflammation?” ...

In the Phase 2 MINDFuL trial of XPro™ in patients with early Alzheimer’s Disease (AD) with biomarkers of inflammation ... s potential in slowing cognitive decline by tackling neuroinflammation.

Demonstrates statistically significant reduction of pro-inflammatory cytokines, including IL-6, IL-1β, IL-2, and ...

InMed stock jumped after preclinical data showed INM-901 lowered brain inflammation tied to Alzheimer's and improved ...

More information: Elisa Nicoloso Simões‐Pires et al, Synergistic effects of the Aβ/fibrinogen complex on synaptotoxicity, neuroinflammation, and blood–brain barrier damage in Alzheimer's ...

A new review suggests that tirzepatide (Mounjaro, Zepbound) may have neuroprotective mechanisms that could help reduce the ...

People living in more disadvantaged neighborhoods may be more likely to have biomarkers for inflammation and Alzheimer's ...

R136S, or the “Christchurch mutation,” appears to protect against Alzheimer’s disease by suppressing inflammatory signaling ...

It would help the trials—and patients—if more people were tested for Alzheimer’s earlier on, so that they could be enrolled to try the new drugs. A single register of those with the disease would also ...

Scientists have long known that the Alzheimer's brain often features abnormal plaques and tangles, and recent studies have highlighted the role that the brain's vascular system plays in disease ...

INmune Bio stock rose sharply on high volume ahead of topline Phase 2 trial data for XPro in early Alzheimer's, expected on June 30.

This evidence lays the foundation for advancing XProTM as a promising treatment option for Alzheimer's disease.” CJ Barnum, PhD, VP of CNS Drug Development, added,“By targeting neuroinflammation, a ...